$519.85
-0.74-0.14%
At close: -
$519.85
0.000.00%
After Hours: 4:02 PM EDT
Comments
Loading...
IDEXX Laboratories Analyst Ratings and Price Targets | NASDAQ:IDXX | Benzinga
IDEXX Laboratories Inc has a consensus price target of $550.27 based on the ratings of 11 analysts. The high is $650 issued by Goldman Sachs on January 17, 2024. The low is $435 issued by Goldman Sachs on July 21, 2022. The 3 most-recent analyst ratings were released by Leerink Partners, Stifel, and Morgan Stanley on June 11, 2025, May 19, 2025, and May 5, 2025, respectively. With an average price target of $549.33 between Leerink Partners, Stifel, and Morgan Stanley, there's an implied 5.67% upside for IDEXX Laboratories Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Leerink Partners
Stifel
Morgan Stanley
Piper Sandler
Barclays
1calculated from analyst ratings
Analyst Ratings for IDEXX Laboratories
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/11/2025 | Buy Now | 11.57% | Leerink Partners | Daniel Clark48% | $515 → $580 | Maintains | Outperform | Get Alert |
| 05/19/2025 | Buy Now | -1.89% | Stifel | Jonathan Block72% | $460 → $510 | Maintains | Hold | Get Alert |
| 05/05/2025 | Buy Now | 7.34% | Morgan Stanley | Erin Wright75% | $548 → $558 | Maintains | Overweight | Get Alert |
| 04/14/2025 | Buy Now | -19.21% | Stifel | Jonathan Block72% | $450 → $420 | Maintains | Hold | Get Alert |
| 02/10/2025 | Buy Now | -1.89% | Piper Sandler | David Westenberg62% | $435 → $510 | Maintains | Neutral | Get Alert |
| 02/04/2025 | Buy Now | 0.03% | Barclays | Balaji Prasad55% | $481 → $520 | Maintains | Overweight | Get Alert |
| 02/04/2025 | Buy Now | 2.91% | B of A Securities | Michael Ryskin47% | $475 → $535 | Maintains | Neutral | Get Alert |
| 01/29/2025 | Buy Now | 5.8% | Morgan Stanley | Erin Wright75% | $559 → $550 | Maintains | Overweight | Get Alert |
| 12/02/2024 | Buy Now | -3.82% | Leerink Partners | Daniel Clark48% | → $500 | Initiates | → Outperform | Get Alert |
| 11/04/2024 | Buy Now | -16.32% | Piper Sandler | David Westenberg62% | $520 → $435 | Reiterates | Neutral → Neutral | Get Alert |
| 11/04/2024 | Buy Now | -7.47% | Barclays | Balaji Prasad55% | $570 → $481 | Maintains | Overweight | Get Alert |
| 10/11/2024 | Buy Now | 10.61% | JP Morgan | Chris Schott59% | $630 → $575 | Maintains | Overweight | Get Alert |
| 10/10/2024 | Buy Now | -3.82% | Stifel | Jonathan Block72% | $510 → $500 | Maintains | Hold | Get Alert |
| 08/14/2024 | Buy Now | 0.03% | Piper Sandler | David Westenberg62% | $600 → $520 | Maintains | Neutral | Get Alert |
| 07/25/2024 | Buy Now | 11.57% | BTIG | Mark Massaro71% | → $580 | Initiates | → Buy | Get Alert |
| 06/24/2024 | Buy Now | -1.89% | Stifel | Jonathan Block72% | $520 → $510 | Maintains | Hold | Get Alert |
| 05/14/2024 | Buy Now | 14.65% | Morgan Stanley | Erin Wright75% | $620 → $596 | Maintains | Overweight | Get Alert |
| 05/02/2024 | Buy Now | 9.65% | Barclays | Balaji Prasad55% | $655 → $570 | Maintains | Overweight | Get Alert |
| 02/06/2024 | Buy Now | 21.19% | JP Morgan | Chris Schott59% | $600 → $630 | Maintains | Overweight | Get Alert |
| 02/06/2024 | Buy Now | 26% | Barclays | Balaji Prasad55% | $605 → $655 | Maintains | Overweight | Get Alert |
| 01/30/2024 | Buy Now | 0.99% | Piper Sandler | David Westenberg62% | → $525 | Downgrade | Overweight → Neutral | Get Alert |
| 01/17/2024 | Buy Now | 25.04% | Goldman Sachs | Nathan Rich42% | $500 → $650 | Maintains | Buy | Get Alert |
| 11/06/2023 | Buy Now | 0.99% | Piper Sandler | David Westenberg62% | $520 → $525 | Maintains | Overweight | Get Alert |
| 11/03/2023 | Buy Now | -3.82% | Goldman Sachs | Nathan Rich42% | $578 → $500 | Maintains | Buy | Get Alert |
| 11/02/2023 | Buy Now | 5.8% | JP Morgan | Chris Schott59% | $600 → $550 | Maintains | Overweight | Get Alert |
| 11/02/2023 | Buy Now | 13.88% | Barclays | Balaji Prasad55% | $590 → $592 | Maintains | Overweight | Get Alert |
| 10/30/2023 | Buy Now | -11.51% | Stifel | Jonathan Block72% | $500 → $460 | Maintains | Hold | Get Alert |
| 09/15/2023 | Buy Now | -3.82% | Stifel | Jonathan Block72% | $525 → $500 | Maintains | Hold | Get Alert |
| 08/03/2023 | Buy Now | 15.42% | Morgan Stanley | Erin Wright75% | $590 → $600 | Maintains | Overweight | Get Alert |
| 08/02/2023 | Buy Now | 15.42% | JP Morgan | Chris Schott59% | $550 → $600 | Maintains | Overweight | Get Alert |
| 08/02/2023 | Buy Now | 15.42% | Atlantic Equities | Steve Chesney53% | → $600 | Downgrade | Overweight → Neutral | Get Alert |
| 06/07/2023 | Buy Now | 15.42% | Atlantic Equities | Steve Chesney53% | → $600 | Reiterates | Overweight → Overweight | Get Alert |
| 05/03/2023 | Buy Now | 15.42% | Atlantic Equities | Steve Chesney53% | → $600 | Reiterates | → Overweight | Get Alert |
| 03/23/2023 | Buy Now | 13.49% | Morgan Stanley | Erin Wright75% | $543 → $590 | Maintains | Overweight | Get Alert |
| 02/08/2023 | Buy Now | 13.49% | Barclays | Balaji Prasad55% | $582 → $590 | Maintains | Overweight | Get Alert |
| 02/07/2023 | Buy Now | 5.8% | JP Morgan | Chris Schott59% | $525 → $550 | Maintains | Overweight | Get Alert |
| 02/07/2023 | Buy Now | 15.42% | Atlantic Equities | Steve Chesney53% | $470 → $600 | Maintains | Overweight | Get Alert |
| 01/25/2023 | Buy Now | 1.95% | Goldman Sachs | Nathan Rich42% | $465 → $530 | Maintains | Buy | Get Alert |
| 11/15/2022 | Buy Now | 4.45% | Morgan Stanley | Erin Wright75% | $573 → $543 | Maintains | Overweight | Get Alert |
| 11/02/2022 | Buy Now | -9.59% | Atlantic Equities | Steve Chesney53% | $490 → $470 | Maintains | Overweight | Get Alert |
| 10/17/2022 | Buy Now | -13.44% | JP Morgan | Chris Schott59% | $525 → $450 | Maintains | Overweight | Get Alert |
| 08/05/2022 | Buy Now | 11.96% | Barclays | Balaji Prasad55% | $700 → $582 | Maintains | Overweight | Get Alert |
| 08/04/2022 | Buy Now | 10.22% | Morgan Stanley | Erin Wright75% | $603 → $573 | Maintains | Overweight | Get Alert |
| 08/03/2022 | Buy Now | -5.74% | Atlantic Equities | Steve Chesney53% | $500 → $490 | Maintains | Overweight | Get Alert |
| 07/26/2022 | Buy Now | -19.21% | Piper Sandler | David Westenberg62% | $440 → $420 | Maintains | Overweight | Get Alert |
| 07/25/2022 | Buy Now | -20.17% | Stifel | Jonathan Block72% | $500 → $415 | Downgrade | Buy → Hold | Get Alert |
| 07/21/2022 | Buy Now | -16.32% | Goldman Sachs | Nathan Rice56% | $530 → $435 | Upgrade | Neutral → Buy | Get Alert |
| 07/12/2022 | Buy Now | -15.36% | Piper Sandler | David Westenberg62% | → $440 | Initiates | → Overweight | Get Alert |
| 06/24/2022 | Buy Now | -3.82% | Stifel | Jonathan Block72% | $575 → $500 | Maintains | Buy | Get Alert |
FAQ
What is the target price for IDEXX Laboratories (IDXX) stock?
The latest price target for IDEXX Laboratories (NASDAQ:IDXX) was reported by Leerink Partners on June 11, 2025. The analyst firm set a price target for $580.00 expecting IDXX to rise to within 12 months (a possible 11.57% upside). 16 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for IDEXX Laboratories (IDXX)?
The latest analyst rating for IDEXX Laboratories (NASDAQ:IDXX) was provided by Leerink Partners, and IDEXX Laboratories maintained their outperform rating.
When was the last upgrade for IDEXX Laboratories (IDXX)?
The last upgrade for IDEXX Laboratories Inc happened on July 21, 2022 when Goldman Sachs raised their price target to $435. Goldman Sachs previously had a neutral for IDEXX Laboratories Inc.
When was the last downgrade for IDEXX Laboratories (IDXX)?
The last downgrade for IDEXX Laboratories Inc happened on January 30, 2024 when Piper Sandler changed their price target from N/A to $525 for IDEXX Laboratories Inc.
When is the next analyst rating going to be posted or updated for IDEXX Laboratories (IDXX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of IDEXX Laboratories, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for IDEXX Laboratories was filed on June 11, 2025 so you should expect the next rating to be made available sometime around June 11, 2026.
Is the Analyst Rating IDEXX Laboratories (IDXX) correct?
While ratings are subjective and will change, the latest IDEXX Laboratories (IDXX) rating was a maintained with a price target of $515.00 to $580.00. The current price IDEXX Laboratories (IDXX) is trading at is $519.85, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
